StockVS

Translational Development Acquisition Corp. (TDAC) 株式分析

金融サービス

Translational Development Acquisition Corp.

$10.64

+$0.00 (+0.00%)

最終更新日: 2026年5月26日

株価推移

分析

企業概要

Translational Development Acquisition Corp. (TDAC) operates as a special purpose acquisition company with no significant current business operations, intending solely to execute a business combination through mergers, amalgamations, or asset acquisitions with one or more target businesses. The company functions within the Financial Services sector, specifically classified under the industry of Shell Companies, which denotes entities created primarily to raise capital for a future merger rather than to conduct immediate commercial activities. As of the latest reporting period, the company holds a market capitalization of $232.22M, while its annual revenue and employee count are listed as N/A, indicating a pre-operational status typical of SPACs. The absence of significant revenue and the lack of reported employee data reflect the transitional nature of the entity, as its market capitalization of $232.22M represents the investor equity committed to the potential business combination rather than earnings from existing operations.

財務健全性

The company reports net income of $6.36M for the trailing twelve months, a figure derived from non-operating sources or specific SPAC accounting treatments since revenue and EBITDA are listed as N/A. The gap between the reported net income and the N/A revenue figures reveals a unique cost structure where traditional operating expenses do not yet align with recognized revenue streams due to the lack of active business operations. Free cash flow stands at $-254,185, indicating that the company is currently burning cash, likely due to transaction costs associated with searching for a target or maintaining its shell status, which limits its immediate financial flexibility for independent investments. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, which is consistent with a shell company that has not yet generated sales or incurred operating expenses relative to revenue in a traditional sense. The company holds $29,787 in cash against a debt level of $200,000, resulting in a current ratio of 0.07, which indicates a severe short-term liquidity constraint where current liabilities significantly outweigh current assets. Furthermore, while the debt-to-equity ratio is listed as N/A, the return on assets is -0.3%, suggesting that the company's asset base is not generating positive returns, and the return on equity is N/A, reflecting the pre-merger stage where traditional management effectiveness metrics are not yet applicable.

バリュエーション評価

The trailing twelve-month P/E ratio is 36.55, whereas the forward P/E is listed as N/A, implying that future earnings expectations cannot be quantified at this stage due to the lack of projected revenue from a specific target business. The price-to-book ratio stands at -7.54, a negative figure that indicates the market valuation is detached from tangible book value, a common characteristic for SPACs that have not yet completed their business combinations. Alternative valuation metrics such as price-to-sales and EV/EBITDA are both N/A, suggesting that these traditional multiples are not applicable until the company transitions from a shell to an operating entity with measurable sales and earnings. The stock price has fluctuated between a 52-week high of $10.60 and a 52-week low of $10.08, with the current trading range situated tightly within this narrow band, reflecting the speculative nature of the investment. The beta is listed as N/A, meaning that the company's price volatility relative to the broader market cannot be calculated with standard metrics until post-merger trading history is established.

Growth & Income

Revenue growth and earnings growth rates are both listed as N/A, as the company has not yet established a historical track record of revenue expansion or earnings acceleration prior to its business combination. Consequently, the comparison between earnings and revenue growth trajectories is not possible at this juncture, as neither metric exists in a traditional sense for a shell company. The company does not pay dividends, with a dividend yield and payout ratio both reported as N/A or 0.0%, indicating that all available capital and future earnings will be reinvested into the business combination process rather than distributed to shareholders. The overall growth and income profile is currently defined by the potential for transformation upon merger, rather than organic growth or income generation, leaving the financial trajectory entirely dependent on the success of the upcoming business combination and the performance of the target entity.

同業他社比較

Translational Development Acquisition Corp. (TDAC) はペーパーカンパニー業界で事業を展開しています。時価総額による最も近い同業他社との比較は以下の通りです:

企業名 ティッカー 時価総額 PER
Translational Development Acquisition Corp. TDAC $233.10M 38.0
Twenty One Capital, Inc. XXI $2.49B N/A
Churchill Capital Corp X CCCX $711.00M N/A
Drugs Made In America Acquisition II Corp. DMII $641.46M 77.5

ペーパーカンパニー業界の平均PERは82.8倍です。Translational Development Acquisition Corp.のPERは38.0です。

この分析はAIによって生成されたものであり、情報提供のみを目的としています。投資アドバイスではありません。データは遅延または不正確な場合があります。投資判断を行う前に、必ずご自身で調査を行い、資格を持つファイナンシャルアドバイザーにご相談ください。

Translational Development Acquisition Corp.について

Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.

企業説明は英語で表示されています。

ウェブサイトを見る →

主要指標

時価総額
$233.10M
PER
38.00
52週高値
$10.69
52週安値
$10.19
平均出来高
8.82K

データはYahoo Financeよりyfinance経由で提供。毎日更新。

企業情報

取引所
NASDAQ
United States